Published in Science on August 26, 1955
The action of reserpine on the peripheral sympathetic system. J Physiol (1958) 4.27
The release of 5-hydroxytryptamine by histamine liberators. Br J Pharmacol Chemother (1956) 2.61
The effect of drugs on the amounts of substance P and 5-hydroxytryptamine in mammalian brain. J Physiol (1956) 2.23
Some central actions of 5-hydroxytryptamine and various antagonists. Br J Pharmacol Chemother (1956) 1.81
The action of 5-hydroxytryptamine, 5-hydroxytryptophan and reserpine on intestinal peristalsis in anaesthetized guinea-pigs. J Physiol (1959) 1.79
THE BETA-ADRENERGIC BLOCKING AND PRESSOR ACTION OF ISOPRENALINE IN THE CAT. Br J Pharmacol Chemother (1963) 1.51
On the concentration of 5-hydroxytryptamine in mammalian enterochromaffin cells and its release by reserpine. J Exp Med (1957) 1.31
Peripheral noradrenaline and adrenergic transmission in the rat. Br J Pharmacol Chemother (1966) 1.26
The interrelation of hypothermia and depletion of noradrenaline, dopamine and 5-hydroxytryptamine from brain by reserpine, para-chlorophenylalanine and alpha-methylmetatyrosine. Br J Pharmacol Chemother (1967) 1.19
ADMINISTRATION OF DIHYDROXYPHENYLALANINE TO PARKINSONIAN PATIENTS. Can Med Assoc J (1964) 1.17
Quantitative evaluation of serotonin release and clearance in Drosophila. J Neurosci Methods (2009) 1.14
A dopaminergic deficit hypothesis of schizophrenia: the path to discovery. Dialogues Clin Neurosci (2006) 0.99
Mechanism of action of reserpine in producing gastric haemorrhage and erosion in the mouse. Br J Pharmacol Chemother (1959) 0.98
Effect of reserpine in therapeutic dosage on excretion of 5-hydroxyindoleacetic acid. Br Med J (1958) 0.92
Neuropharmacological agents modifying endotoxin-induced changes in mice. J R Soc Med (1980) 0.92
The role of pharmacologically-active amines in resistance to Trichostrongylus colubriformis in the guinea-pig. Immunology (1971) 0.87
Electrochemical quantification of serotonin in the live embryonic zebrafish intestine. Anal Chem (2010) 0.86
The presence of a 5-hydroxytryptamine (serotonin) liberator in the gastro-intestinal tract. J Physiol (1957) 0.85
Depletion and replacement of the adrenaline and noradrenaline contents of the rat adrenal gland, following treatment with reserpine. Br J Pharmacol Chemother (1962) 0.85
The vesicular monoamine transporter 2: an underexplored pharmacological target. Neurochem Int (2014) 0.84
Content and subcellular localization of catecholamines and 5-hydroxytryptamine in human and animal blood platelets: monoamine distribution between platelets and plasma. Br J Pharmacol (1979) 0.84
Amines and abnormal mood. Proc R Soc Med (1969) 0.83
Vesicular integrity in Parkinson's disease. Curr Neurol Neurosci Rep (2013) 0.82
Drug prophylaxis in migraine. A controlled clinical trial. Br Med J (1960) 0.81
Release of 5-hydroxytryptamine by pentagastrin and its role in the 'fade' of stimulated gastric secretion in cats. J Physiol (1987) 0.81
The comparative pharmacology of some psychotropic drugs. Bull World Health Organ (1959) 0.75
The Role of Serotonin in the Central Nervous System. Can Med Assoc J (1956) 0.75
Some effects of reserpine and hydraliazine upon tissue respiration and the concentration of adenosine nucleotides in certain tissues. Br J Pharmacol Chemother (1959) 0.75
Reserpine methonitrate, a novel quaternary analogue of reserpine augments urinary excretion of VMA and 5-HIAA without affecting HVA in rats. BMC Pharmacol (2004) 0.75
Effect of hypotensive drugs and hypophysectomy upon the adrenal cortex of normal and hypertensive dogs. Ann Surg (1961) 0.75
Mechanism of neurotoxicity of cardiotonic glycosides. Br J Pharmacol (1977) 0.75
Current drug therapy of essential hypertension in relation to some of the non-renal factors which participate in the maintenance of blood pressure. Postgrad Med J (1957) 0.75
Experience with reserpine (serpasil) and perphenazine (trilafon) in acute alcoholic intoxications and alcoholic psychosis. Can Med Assoc J (1958) 0.75
The management of emotional disorders by the general practitioner. J Natl Med Assoc (1959) 0.75
Serotonin and brain function: a tale of two receptors. J Psychopharmacol (2017) 0.75
A simplified method for the estimation of total cholesterol in serum and demonstration of its specificity. J Biol Chem (1952) 18.27
A method for the fluorometric assay of histamine in tissues. J Pharmacol Exp Ther (1959) 16.61
The physiological disposition and metabolic fate of hydrocortisone in man. J Clin Invest (1955) 6.74
Ascorbic acid in aromatic hydroxylation. I. A model system for aromatic hydroxylation. J Biol Chem (1954) 5.08
Identification and assay of serotonin in brain. J Pharmacol Exp Ther (1956) 4.17
The gastric secretion of drugs: a pH partition hypothesis. J Pharmacol Exp Ther (1957) 3.99
The physiological disposition of phenylbutazone (butazolidin) in man and a method for its estimation in biological material. J Pharmacol Exp Ther (1953) 3.60
A chemical method for the determination of free choline in plasma. J Biol Chem (1953) 3.57
Norepinephrine depletion as a possible mechanism of action of guanethidine (SU 5864), a new hypotensive agent. Proc Soc Exp Biol Med (1960) 3.26
On the mechanism of intestinal absorption of drugs. J Pharmacol Exp Ther (1959) 3.16
Some physico-chemical factors in drug action. J Pharm Pharmacol (1957) 3.13
The fate of antipyrine in man. J Pharmacol Exp Ther (1950) 3.05
The direct determination of phosphatidyl ethanolamine and phosphatidyl serine in plasma and red blood cells. J Biol Chem (1953) 2.98
Ascorbic acid in aromatic hydroxylation. II. Products formed by reaction of substrates with ascorbic acid, ferrous ion, and oxygen. J Biol Chem (1954) 2.78
INTERACTION OF GUANETHIDINE WITH ADRENERGIC NEURONS. J Pharmacol Exp Ther (1965) 2.77
A concept for a role of serotonin and norepinephrine as chemical mediators in the brain. Ann N Y Acad Sci (1957) 2.71
Absorption of drugs from the rat small intestine. J Pharmacol Exp Ther (1958) 2.62
The fate of aminopyrine (pyramidon) in man and methods for the estimation of aminopyrine and its metabolites in biological material. J Pharmacol Exp Ther (1950) 2.54
The oxidation of drugs by liver microsomes: on the role of TPNH and oxygen. J Pharmacol Exp Ther (1957) 2.46
The fate of pentobarbital in man and dog and a method for its estimation in biological material. J Pharmacol Exp Ther (1953) 2.38
Identification and chemical assay of norepinephrine in brain and other tissues. J Pharmacol Exp Ther (1958) 2.37
Enzymatic metabolism of drugs and other foreign compounds. Annu Rev Biochem (1958) 2.36
Serotonin as a mediator of reserpine action in brain. J Pharmacol Exp Ther (1956) 2.26
A potent new uricosuric agent, the sulfoxide metabolite of the phenylbutazone analogue, G-25671. J Pharmacol Exp Ther (1957) 2.20
Detoxication of drugs and other foreign compounds by liver microsomes. Science (1955) 2.20
Estimation of intracellular water in man. Am J Physiol (1950) 2.14
Evidence that serotonin has a role in brain function. Science (1955) 2.13
Pharmacological consequences of the selective release of peripheral norepinephrine by syrosingopine (Su 3118). J Pharmacol Exp Ther (1960) 2.10
The fate of thiopental in man and a method for its estimation in biological material. J Pharmacol Exp Ther (1950) 2.10
Interaction of reserpine, serotonin, and lysergic acid diethylamide in brain. Science (1955) 1.99
Absorption of drugs from the stomach. I. The rat. J Pharmacol Exp Ther (1957) 1.86
Absorption of drugs from the stomach. II. The human. J Pharmacol Exp Ther (1957) 1.85
Mechanism of the potentiating action of beta-diethylaminoethyl diphenylpropylacetate. J Pharmacol Exp Ther (1954) 1.78
Enzymatic dealkylation of aminopyrine (pyramidon) and other alkylamines. J Biol Chem (1955) 1.77
The metabolic fate of phenylbutazone (butazolidin) in man. J Pharmacol Exp Ther (1955) 1.76
Biochemical and pharmacological studies of RO 1-9569 (tetrabenazine), a nonindole tranquilizing agent with reserpine-like effects. J Pharmacol Exp Ther (1959) 1.63
The physiological disposition and metabolic fate of cortisone in man. J Clin Invest (1957) 1.62
On the mechanism of drug potentiation by iproniazid (2-isopropyl-1-isonicotinyl hydrazine). J Pharmacol Exp Ther (1956) 1.61
Physiological disposition and fate of chlorpromazine and a method for its estimation in biological material. J Pharmacol Exp Ther (1956) 1.59
BINDING AND RELEASE OF METARAMINOL: MECHANISM OF NOREPINEPHRINE DEPLETION BY ALPHA-METHYL-M-TYROSINE AND RELATED AGENTS. J Pharmacol Exp Ther (1964) 1.56
The enzymatic metabolism of hexobarbital (evipal). J Pharmacol Exp Ther (1955) 1.56
Possible interrelationship between release of brain norepinephrine and serotonin by reserpine. Science (1957) 1.54
Release of serotonin and catecholamines by drugs. Pharmacol Rev (1962) 1.53
Total body water in man. Am J Physiol (1950) 1.50
[Etiology and prophylaxis of occupational tumors in dye workers]. Schweiz Med Wochenschr (1954) 1.49
Inhibitory effects of beta-diethylaminoethyl diphenylpropylacetate on a variety of drug metabolic pathways in vitro. J Pharmacol Exp Ther (1954) 1.49
The importance of dissociaton constant and lipid-solubility in influencing the passage of drugs into the cerebrospinal fluid. J Pharmacol Exp Ther (1960) 1.47
RECENT VIEWS ON MECHANISMS FOR LOWERING SYMPATHETIC TONE. Circulation (1963) 1.44
On the mechanism of antidepressant action of imipraminelike drugs. Ann N Y Acad Sci (1962) 1.42
The use of procaine amide in cardiac arrhythmias. Circulation (1951) 1.42
Pathways of drug metabolism. J Pharm Pharmacol (1956) 1.41
Biochemical and pharmacological effects of the monoamine oxidase inhibitors, iproniazid, 1-phenyl-2-hydrazinopropane (JB 516) and 1-phenyl-3-hydrazinobutane (JB 835). J Pharmacol Exp Ther (1960) 1.41
The mechanism of serotonin and catecholamine uptake by platelets. J Pharmacol Exp Ther (1959) 1.40
Role of brain serotonin in reserpine action. Ann N Y Acad Sci (1957) 1.40
Structural requirements for bretylium and guanethidine-like activity. Life Sci (1962) 1.39
Release of serotonin from blood platelets by reserpine in vitro. J Pharmacol Exp Ther (1957) 1.39
The enzymatic reduction of chloramphenicol, p-nitrobenzoic acid and other aromatic nitro compounds in mammals. J Pharmacol Exp Ther (1957) 1.38
Metabolism of drugs in subjects with Laennec's cirrhosis. Med Exp Int J Exp Med (1959) 1.38
Postoperative pain; its use in the comparative evaluation of analgesics. Surgery (1952) 1.38
Assay of serotonin and related metabolites, enzymes, and drugs. Methods Biochem Anal (1958) 1.37
Microanalytical procedures for fluorometric assay of brain DOPA-5HTP decarboxylase, norepinephrine and serotonin, and a detailed mapping of decarboxylase activity in brain. J Neurochem (1961) 1.35
The physiological disposition and biotransformation of dibenamine and a method for its estimation in biological tissues. J Pharmacol Exp Ther (1952) 1.35
RELEASE OF METARAMINOL (ARAMINE) FROM THE HEART BY SYMPATHETIC NERVE STIMULATION. Science (1964) 1.33
The role of body fat in limiting the duration of action of thiopental. J Pharmacol Exp Ther (1952) 1.32
MECHANISM OF ACTION OF RESERPINE AND INSULIN ON GASTRIC AMINES AND GASTRIC ACID SECRETION, AND THE EFFECT OF MONOAMINE OXIDASE INHIBITION. J Pharmacol Exp Ther (1963) 1.28
Influence of chlorpromazine and chlorprothixene on the cerebral metabolism of 5-hydroxytryptamine, norepinephrine and dopamine. J Pharmacol Exp Ther (1961) 1.27
Reserpine and guanethidine action on peripheral stores of catecholamines. Life Sci (1962) 1.27
Diminution of 5-hydroxytryptamine in thrombocytes in vitro by chlorpromazine and related compounds. Experientia (1961) 1.24
Observations on the antirheumatic and physiologic effects of phenylbutazone (butazolidin) and some comparisons with cortisone. Am J Med (1954) 1.22
Effects of reserpine and cold-exposure on pituitary-adrenocortical function in rats. J Pharmacol Exp Ther (1961) 1.21
CHLORINATED ARYLALKYLAMINES AFFECTING THE CEREBRAL METABOLISM OF 5-HYDROXYTRYPTAMINE. J Pharmacol Exp Ther (1964) 1.21
THE ACTIONS OF RESERPINE, GUANETHIDINE AND METARAMINOL ON CARDIAC CATECHOLAMINE STORES. Life Sci (1964) 1.18
Enzymatic reduction of prontosil and other azo dyes. J Pharmacol Exp Ther (1957) 1.17
The physiological disposition of dicumarol in man. J Pharmacol Exp Ther (1950) 1.17
Interaction of monoamine oxidase inhibitors with physiological and biochemical mechanisms in brain. Ann N Y Acad Sci (1959) 1.17
Role for ganglionic norepinephrine in sympathetic synaptic transmission. Science (1961) 1.15
Interaction of drugs with norepinephrine in the brain. Pharmacol Rev (1959) 1.15
Storage synthesis, and metabolism of monoamines in the developing brain. J Neurochem (1962) 1.14
Quinoline and its transformation products found in urine. J Biol Chem (1950) 1.14
Interaction of serotonin and lysergic acid diethylamide (LSD) in the central nervous system. Experientia (1955) 1.14